Returning investor BGI took part in a series B round for the cancer diagnostics technology developer that included fellow corporate UEC.
China-based cancer diagnostics technology developer Gene+ Technology has secured RMB200m ($28m) in a series B round featuring genome sequencing technology provider BGI and IT services firm UEC, China Money Network has reported.
Private equity firm Co-Stone Asset Management led the round, which included Volcanics Venture, Green Pine Capital Partners and Desun Asset.
Gene+ has developed a gene-testing platform that detects signs of cancer at an early stage and which can be used to monitor for signs of recurrence. The technology…
